The EXCEL and NOBLE trials: Similarities, contrasts and future perspectives for left main revascularisation

Carlos M. Campos, Evald H. Christiansen, Gregg W. Stone, Patrick W. Serruys

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Unprotected left main coronary artery (ULMCA) stenosis has relatively high prevalence and exposes patients to a high risk for adverse cardiovascular events. The optimal revascularisation strategy (coronary artery bypass surgery [CABG] or percutaneous coronary intervention [PCI]) for patients with complex coronary artery disease is a topic of continuing debate. The introduction of the newer-generation drug-eluting stents (DES) -with documented improvements in both safety and efficacy -has prompted the interventional community to design two new dedicated randomised trials comparing CABG and PCI: the NOBLE (Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis) and EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trials. The aims of the present review are to describe the similarities and contrasts between these two trials as well to explore their future implications in ULMCA treatment.

Original languageEnglish
Pages (from-to)V115-V119
JournalEuroIntervention
Volume11
DOIs
StatePublished - 1 May 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'The EXCEL and NOBLE trials: Similarities, contrasts and future perspectives for left main revascularisation'. Together they form a unique fingerprint.

Cite this